# Appraising clinicopathological and prognostic significance of circular RNA ubiquitin-associated protein 2 in human cancer.

- **DOI:** [10.1186/s12957-025-04118-0](https://doi.org/10.1186/s12957-025-04118-0)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** A competent first circUBAP2 biomarker synthesis that organizes scattered cancer evidence, but its pan-cancer inference remains preliminary.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-07-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs12957-025-04118-0

## Strengths

- **First synthesis of circUBAP2 evidence** The Introduction identifies the absence of prior meta-analysis on circUBAP2 in human cancer, and the Results aggregate 12 studies covering clinicopathological features and survival outcomes. This gives the paper a clear role as an initial evidence map for a narrow biomarker question.
  - Dimension: contribution
  - Location: Introduction; Results, Characteristics of Included Studies; Table 1
- **Core systematic-review procedures reported** The Methods state OSF registration, PRISMA checklist use, searches across PubMed, Web of Science, CNKI, Wanfang, ClinicalTrials.gov, and BioXiv, plus dual screening and extraction with adjudication. These features support a competent baseline evidence-synthesis workflow.
  - Dimension: methodological rigour
  - Location: Methods, Search Strategies; Methods, Selection Process; Methods, Data Extraction
- **Limitations are explicitly acknowledged** The Discussion identifies a small total evidence base, survival information extracted from curves, and underpowered cancer-specific strata. This helps readers interpret the pooled pan-cancer estimates as preliminary rather than definitive.
  - Dimension: positioning
  - Location: Discussion, Limitations

## Limitations

- **Certainty framework is missing** The review does not report GRADE or an equivalent certainty-of-evidence assessment despite drawing clinically relevant prognostic conclusions. This limits how clearly readers can distinguish statistical significance from confidence in the evidence base.
  - Dimension: methodological rigour
  - Location: Methods; Results; Discussion
- **Pan-cancer pooling limits clinical specificity** The included studies span multiple tumor types with small individual strata, and some outcomes are represented by only one or two studies. The broad pooled associations therefore do not establish reliable tumor-specific clinical utility.
  - Dimension: application pathway
  - Location: Results, Table 1; Results, Table 3; Discussion, Limitations
- **Reporting precision has notable lapses** The Search Process exclusion counts do not reconcile exactly, Table 3 uses a fixed-effects model for a subgroup with I²=52.5% despite the stated model rule, and the Discussion contains awkward or garbled wording. These issues do not overturn the main results but reduce confidence in reporting discipline.
  - Dimension: reporting
  - Location: Results, Search Process; Methods, Statistical Analysis; Table 3; Discussion

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The paper is broadly internally interpretable and the main pooled estimates are consistently reported, but several reporting issues reduce confidence in exactness. These include inconsistent exclusion arithmetic, an effects-model inconsistency in one survival subgroup, overconfident publication-bias language, and minor citation/editing problems.
- **Research conduct:** Noted. The review reports OSF registration, PRISMA alignment, dual screening, and dual extraction, but reproducibility and conduct reporting are incomplete. Data and code availability are not provided, conflict-of-interest reporting is not visible in the supplied text, and protocol-to-report consistency cannot be verified from the article alone.
- **Reference integrity:** Clean. All 31 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
